BSD Medical Corporation (NASDAQ:BSDM) today announced that their published study results demonstrated improvement in the overall survival, tumor response rates, and local tumor control from the addition of hyperthermia therapy delivered through BSD-2000 Hyperthermia System. This therapy was delivered as a standard treatment regimen for the 45 patients suffering from high-risk bladder cancer.
http://www.favstocks.com/bsd-medicals-hy...
The multi-institutional study was named as Quadrimodal treatment of high risk T1 and T2 bladder cancer. The research was conducted by eight well-known medical researchers who are the front-runners in the field of oncology research. The study was conducted at three prestigious medical centers one being one of the largest universities in Germany, University of Erlangen, which provides an unique range of interdisciplinary research, and also at University of Frankfurt and Hospital Martha-Maria in Germany. The study was published in Radiotherapy and Oncology which is the official publication of the European Society for Therapeutic Radiology and Oncology.